Teriparatide (PTH 1–34) attached to an inert polyethylene glycol carrier through a linker that slowly breaks apart, releasing PTH steadily around the clock. It replaces the missing hormone in hypoparathyroidism, keeping blood calcium normal.
Evidence. Approved in the EU (November 2023) and the US (August 2024) as Yorvipath for adults with hypoparathyroidism, and since in the UK, Australia and Canada. In the 26-week PaTHway trial (82 adults), 68.9% vs 4.8% on placebo kept normal calcium without active vitamin D or high-dose calcium, by FDA’s count. FDA first turned it down in April 2023 over variable pen doses.
What it’s used for
Approved uses first, then uses tested in people, then claims that rest on animal studies or user reports.
Hypoparathyroidism in adults
LabelApproved for adults. At 26 weeks, 68.9% vs 4.8% on placebo had normal calcium without active vitamin D or high-dose calcium by FDA’s count (79% vs 5% in the published analysis).
Protecting kidney function
TrialPromising, unproven: in a post hoc look at PaTHway, eGFR, a kidney filtering measure, rose 9.0 points by 2 years with no comparison group, and urine calcium stayed normal.
Hypoparathyroidism symptoms and quality of life
TrialPositive: in PaTHway, symptom and functioning scores on a hypoparathyroidism-specific scale improved more than on placebo over 26 weeks, as did physical functioning on the SF-36 survey.
Low calcium right after neck surgery
No studyNot studied: the US label says it wasn’t tested for acute hypoparathyroidism after surgery, and its dosing scheme assumes calcium was first stabilized.
Osteoporosis or building bone
No studyNot a use: it gives steady all-day PTH rather than daily pulses. In trials, high starting bone density fell toward normal, and in rats some doses caused net bone loss.
Hypoparathyroidism in children
No studyNot approved under 18, and no trial results yet: a European trial in teens aged 12–17 began in April 2026.
Label: an approved use. Trial: tested in people, with the result. No study: nothing published supports it.
Approved in the US on August 9, 2024 as Yorvipath for hypoparathyroidism in adults, after a 2023 rejection over variable pen doses. Not approved for children, and not studied for low calcium right after neck surgery.
Approval history
2023EU (EMA): Yorvipath: chronic hypoparathyroidism in adults (orphan medicine)
2024US FDA: Yorvipath: hypoparathyroidism in adults, after a 2023 rejection over pen dosing
2025Australia: Yorvipath: chronic hypoparathyroidism in adults
European Union
EMA-authorised orphan medicine since November 2023 for adults with chronic hypoparathyroidism, at 6–60 mcg a day. The older PTH(1–84) product, Natpar, was withdrawn in July 2026.
United Kingdom
Prescription-only medicine (MHRA): Yorvipath, licensed April 2024 for adults with chronic hypoparathyroidism, at 6–60 mcg a day.
Canada
Prescription drug: Health Canada lists Yorvipath pens as marketed since April 10, 2026 (one strength approved in January 2026, not yet marketed).
Australia
Prescription only (Schedule 4). Yorvipath registered February 2025 for adults with chronic hypoparathyroidism, at 6–60 mcg a day.
Sport (WADA 2026)
Not banned in sportNot named on the 2026 list, and S0 doesn’t apply to an approved drug. Parathyroid hormone and its analogs aren’t among the S2 peptide hormones or growth factors the list names.
Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
How it works
Palopegteriparatide is teriparatide, the active first 34 amino acids of parathyroid hormone (PTH), tied to an inert polyethylene glycol carrier by a linker that breaks apart on its own in the body, releasing PTH steadily over the day. Like natural PTH, it acts on the PTH1 receptor in bone and kidney: it frees calcium from bone, makes the kidneys keep calcium and shed phosphate, and boosts active vitamin D, which raises calcium absorption.
LabelBased on the product label.
Not known
Long-term effects on bone, kidney outcomes and fracture risk are still being studied; the kidney-function gains come from uncontrolled extension data. No long-term cancer studies in animals have been done.
Protocol
Label
Yorvipath (US)
Starts at 18 mcg once a day, then moves up or down in 3 mcg steps by blood calcium (up no sooner than every 7 days, down no sooner than every 3). Usual range 6–30 mcg, always one injection; active vitamin D and calcium pills are cut back on day 1.
Label
Yorvipath (EU, UK, Australia)
Same start and steps, but the range runs to 60 mcg a day; doses above 30 mcg are given as two injections from two pens at different sites.
Frequency
Once daily
Route
Subcutaneous injection (abdomen or front of thigh)
Timing
Once a day. If dizziness or a pounding heart follows injections, the label suggests dosing at bedtime while lying down.
Cycle
Continuous. It replaces a missing hormone, so the labels treat it as long-term therapy; stopping suddenly can drop blood calcium.
Week 15913172125
Continuous, shown over 26 weeks
Common protocols
The ways Palopegteriparatide is most often run, each tagged with where it comes from.
US dosing (one injection a day)
Label
Dose
6–30 mcg (starts at 18 mcg)
How often
Once daily
How long
Long-term
Adjusted in 3 mcg steps by blood calcium. If calcium stays low at 30 mcg, the label says to add back calcium or active vitamin D, not to inject twice.
EU, UK and Australia
Label
Dose
6–60 mcg (starts at 18 mcg)
How often
Once daily
How long
Long-term
Doses above 30 mcg are given as two injections from two pens, one after the other, at different sites.
Taking it
Where it goes
Under the skin of the belly or front of the thigh, rotating daily among four sites: left or right belly and left or right thigh (EU label). The needle stays in for 5 seconds after each dose (instructions for use).
If you miss a dose
Label: if a dose is less than 12 hours late, take it as soon as possible; if more than 12 hours, skip it and take the next dose as scheduled. After 3 or more days without doses, watch for low calcium and check calcium when restarting.
Active vitamin D is cut by at least half or stopped, and calcium pills reduced, on the first day, following the label’s chart.
Label
Days 7–10
First blood calcium check, repeated 7–10 days after every dose change. Steady PTH levels are reached after about 7 days.
Label
Week 26
68.9% vs 4.8% on placebo had normal calcium without active vitamin D or high-dose calcium (FDA analysis); symptomatic high calcium affected 8%, all in the first 3 months.
Label
Years 1–2
In the open-label extension, 81% met the goal at week 52; urine calcium stayed normal and eGFR, a kidney filtering measure, rose about 9 points by week 104, without a comparison group.
Trial
Side effects and what to do
Injection-site reactions (label: 39% vs 5% on placebo)
Mostly mild redness lasting about 3 days. Rotate sites daily.
Dizziness, palpitations or blood pressure drops on standing (label: 28% vs 0%)
Mostly in the first 3 months. The label suggests dosing at bedtime while lying down.
Headache (label: 21% vs 10%)
Common early on; it can also come with high calcium.
High blood calcium (label: above normal at some point in 54% vs 9.5%; above 12 mg/dL in 13% vs 0%)
Nausea, vomiting, thirst, confusion or weakness can be signs. Above 12 mg/dL the label says to hold doses for 2–3 days and recheck.
Low blood calcium (common in the EU label)
Tingling of the lips, fingers or toes, muscle cramps or spasms can be signs, especially after missed or stopped doses; contact the care team promptly.
Stop and get medical help
Swelling of the face, lips or throat, hives or trouble breathing: stop and get emergency care (label). Seizures, severe muscle spasms or an irregular heartbeat (low calcium), or vomiting, confusion or extreme thirst (high calcium), need urgent care.
By the numbers
From the trials in the Yorvipath label. Side effects count everything reported, whatever the cause, so the gap between the placebo and drug columns is what the drug adds.
Side effects vs placebo
Side effects over 26 weeks in adults: those in at least 5% on Yorvipath and at least 2 points more common than on placebo. Figures are the % of people.
Side effect
Placebon=21
Yorvipathn=61
Injection-site reactions
5
39
Dizziness, palpitations or blood pressure drops on standing
0
28
Headache
10
21
Diarrhea
5
10
Back pain
0
8
High blood calcium
0
8
Sore throat
0
7
Some rows group related terms: injection-site reactions include bruising, redness and rash; the dizziness row also counts fainting, near-fainting and vertigo; back pain includes flank and spine pain.
Blood calcium above normal (over 10.6 mg/dL) at least once: 54.1% vs 9.5% on placebo; above 12 mg/dL: 13.1% vs 0%.
High calcium with symptoms affected 8% on Yorvipath, all in the first 3 months.
Over a mean 850 days, 1 of 139 (0.7%) developed low-level antibodies to PTH and 7 (5%) to PEG, the drug’s carrier; 3 with existing PEG antibodies needed dose changes.
Results
Week 26 results in adults with hypoparathyroidism, counting everyone randomized; the main goal required meeting every target listed.
Measure
Placebo
Yorvipath
Difference, points (95% CI)
Met the main goal
4.8%
68.9%
64.2 (49.5 to 78.8)
Normal blood calcium
47.6%
80.3%
32.7 (9.2 to 56.3)
Off active vitamin D
23.8%
95.1%
71.3 (52.5 to 90.2)
Calcium pills at 600 mg a day or less
4.8%
86.9%
82.2 (70.0 to 94.4)
No dose increase in the last 4 weeks
57.1%
93.4%
36.4 (14.2 to 58.5)
21 on placebo and 61 on Yorvipath; both groups began on their usual calcium and active vitamin D, then adjusted to blood calcium. The goal also required staying at 30 mcg a day or less, met by 91.8% on Yorvipath.
How the body handles it
Release
A prodrug: its carrier releases PTH(1–34) steadily, so levels stay up across the whole day
Peak level
A median 4 hours (4 to 8) after a dose
Steady level
Reached after 7 days of daily doses
Half-life
About 60 hours for the released PTH
Spread in the body
About 4.8 L (apparent volume of distribution)
Cleared by
About 0.58 L a day (apparent clearance); mild to severe kidney impairment made no meaningful difference to exposure
Source: Yorvipath prescribing information (revised 08/2026). Trials of different drugs enrolled different people, so compare across drugs with care.
Can it cause …?
The side effects people ask about most, answered one by one. Each answer says where it comes from.
Tiredness
LabelFatigue is very common (over 1 in 10) and weakness common in the EU label. Tiredness can also signal high or low calcium.
Headache
LabelHeadache 21% vs 10% on placebo in the US label; 18.7% across trials in the EU label.
Nausea or vomiting
LabelNausea is very common (over 1 in 10) in the EU label, mostly in the first 3 months; vomiting is common. Nausea can also signal high calcium.
Diarrhea or constipation
LabelDiarrhea 10% vs 5% on placebo in the US label; constipation and belly pain are common in the EU label.
Dizziness
LabelDizziness, fainting or blood pressure drops on standing: 28% vs 0% on placebo, mostly in the first 3 months. The label suggests dosing at bedtime, lying down.
Trouble sleeping
Not reportedTrouble sleeping isn’t listed in the US or EU labels; the main trial treated 61 adults for 26 weeks before an open-label extension.
Hair loss
Not reportedHair loss isn’t listed in the labels; the main trial treated 61 adults for 26 weeks before an open-label extension.
Acne, rash or skin changes
LabelInjection-site reactions 39% vs 5% on placebo, mostly mild redness lasting about 3 days; rash and sensitivity to sunlight are common in the EU label.
Water retention or swelling
LabelInjection-site swelling is among the common injection reactions. Face or throat swelling (angioedema) has been reported as an allergic reaction (US label, 2026).
Joint or muscle pain
LabelBack pain 8% vs 0% on placebo (US label); joint pain, muscle pain and muscle twitching are common (EU). Twitching and cramps can signal low calcium.
Anxiety, low mood or irritability
LabelNot a listed side effect, but low mood and trouble thinking are listed signs of low calcium. In PaTHway, hypoparathyroidism symptom scores improved more than on placebo.
Low or high blood sugar
Not reportedBlood sugar changes aren’t listed in the labels; the main trial treated 61 adults for 26 weeks before an open-label extension.
Fast heartbeat or blood pressure changes
LabelPalpitations, a fast heartbeat on standing and blood pressure drops are common, mostly early on; high blood pressure is uncommon and tied to high calcium (EU label).
More hunger
Not reportedMore hunger isn’t listed in the labels; the main trial treated 61 adults for 26 weeks before an open-label extension.
Liver strain
Not reportedLiver strain isn’t listed in the labels; severe liver impairment hasn’t been studied.
Kidney problems
TrialIn an uncontrolled 2-year analysis, urine calcium normalized and eGFR, a kidney filtering measure, rose about 9 points. Getting up at night to urinate is uncommon (EU label).
Cancer risk
LabelNo long-term cancer studies were done. Related PTH drugs caused osteosarcoma in rats, though studies of teriparatide users found no rise; the label avoids it in people at higher risk.
Label: from the prescribing information. Trial: reported in human studies. Not reported: studied in people and not reported. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
Who should avoid it
What its label rules out or warns about, most important first.
Severe allergy to palopegteriparatide
LabelRuled out by the US label; anaphylaxis, angioedema (deep swelling of the face or throat) and hives have been reported, and a hypersensitivity warning was added in August 2026.
Pseudohypoparathyroidism
LabelRuled out by the EU label. In this condition PTH levels are high, but the body resists their effects.
Higher baseline risk of bone cancer
LabelNot recommended (US) with open growth plates, Paget’s disease or other metabolic bone disease, unexplained high alkaline phosphatase, bone cancer or metastases, or past skeletal radiation.
Severe kidney or liver impairment
LabelNot studied in hypoparathyroidism with eGFR under 30 or in severe liver disease; the EU label advises caution and closer calcium checks when eGFR is under 45.
Pregnancy or breastfeeding
LabelToo few data to judge risk. Low or high maternal calcium carries its own risks, so calcium is monitored closely; the US label says to watch breastfed babies’ calcium.
Low calcium right after neck surgery
LabelNot studied for acute post-surgical hypoparathyroidism, and its dosing scheme was tested only after calcium was first stabilized at 7.8 mg/dL or higher (US label).
Interactions
Only interactions stated on a product label or measured in a human study are listed.
Digoxin (a heart drug)
LabelHigher calcium can cause digoxin toxicity and low calcium can blunt its effect; the label says to check calcium and digoxin levels and watch for toxicity.
Drugs that change blood calcium (thiazide and loop water pills, steroid pills, lithium, bisphosphonates, denosumab, romosozumab)
LabelThey may alter its effect, so the labels advise checking calcium more often, especially when these drugs are started, stopped or changed.
Label: a product label rules it out, warns about it or lists the interaction. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
Special situations
What the label and studies say about pregnancy, breastfeeding, kidney and liver problems, age and surgery.
Pregnancy
LabelData are too limited to judge risk; animal studies showed no harm at 13–16 times human exposure. Maternal low calcium has its own risks, so calcium is monitored closely, and a pregnancy registry began in 2026.
Breastfeeding
LabelNo data on milk. The US label says to watch breastfed babies for high or low calcium and consider testing them; the EU label calls harm unlikely because it isn’t absorbed by mouth. A milk study is under way.
Kidney problems
LabelNo dose change down to eGFR 15 (US) or 30 (EU); a single dose gave similar PTH exposure in severe impairment. Not studied in hypoparathyroidism with eGFR under 30; the EU advises closer calcium checks below 45.
Liver problems
LabelNo dedicated study. The US label doesn’t expect mild or moderate impairment to matter; the EU label urges caution in severe impairment, which wasn’t studied.
Older adults
LabelOnly 8 of the 61 treated people in the main trial were 65 or older, too few to tell whether older adults respond differently.
Children and teens
LabelNot approved under 18; safety and effectiveness aren’t established, and the US Medication Guide says not to use it while bones are still growing. A trial in teens 12–17 began in 2026.
Surgery and anesthesia
PrecautionNo label advice. It sets blood calcium, and 3 or more days without doses can drop calcium; tell the surgical team, who may need to check calcium around surgery.
Label: what the prescribing information says. Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.
Tracking and pairing
Worth tracking
Albumin-corrected blood calcium 7–10 days after any dose change, then at least every 4–6 weeks (label)
25-hydroxy vitamin D and calcium in the 2 weeks before the first dose (label)
Daily watch for symptoms of high or low calcium (label)
Calcium and digoxin levels if taking digoxin (label)
Often paired with
Usually run on its own.
Human studies
5 key published human studies, with how many people took part. Animal studies aren’t listed here.
202382 people
79% vs 5% on placebo had normal calcium without active vitamin D or therapeutic calcium (68.9% vs 4.8% by FDA’s stricter definition); 93% stopped conventional therapy.
18 mcg daily to start, adjusted by blood calcium; 92% stayed at 30 mcg or less
Length
26 weeks
Khan et al., J Bone Miner Res 2023, PMID 36271471
202582 people
81% of the 78 still treated met the composite goal and 95% were free of conventional therapy; urine calcium fell from 376 to 195 mg/day.
Design
Open-label extension of PaTHway
Dose
Individually adjusted daily dose
Length
52 weeks
Clarke et al., J Clin Endocrinol Metab 2025, PMID 39376010
202682 people
eGFR rose a mean 9.0 mL/min/1.73 m² from baseline; 97% of those still treated were free of conventional therapy, and urine calcium stayed under 250 mg/day.
Design
Post hoc analysis of the PaTHway open-label extension
Dose
Individually adjusted daily dose
Length
104 weeks
Rejnmark et al., J Bone Miner Res 2026, PMID 42166177
202259 people
91% were free of standard therapy by week 26, and urine calcium fell from 415 to 178 mg per 24 hours.
Design
Randomized double-blind placebo-controlled phase 2 trial (4 weeks) with an open-label extension (PaTH Forward)
Dose
15, 18 or 21 mcg daily, then adjusted (6–60 mcg)
Length
26 weeks
Khan et al., J Clin Endocrinol Metab 2022, PMID 34347093
202659 people
91% of the 57 still treated were free of conventional therapy; bone density fell from above-normal levels toward age norms, mostly in the first 26 weeks.
Design
Open-label extension of the PaTH Forward phase 2 trial
Dose
Individually adjusted daily dose
Length
162 weeks
Rubin et al., J Bone Miner Res 2026, PMID 41636590
Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.
Phase 3NCT07081997
Doses above 30 mcg a day in 36 adults already needing 30 mcg or more, over 78 weeks
Recruiting since May 2026; completion expected June 2028
Phase 3NCT07706764
Single-arm trial in 12 teens aged 12–17 with chronic hypoparathyroidism, in Europe, over 234 weeks: safety and calcium control
Recruiting since April 2026; primary completion expected August 2027
Phase 3NCT05387070
PaTHway China: palopegteriparatide vs placebo for 26 weeks, then open-label, in 81 Chinese adults
Completed January 2026; no results posted
ObservationalNCT07264634
How much palopegteriparatide passes into breast milk, in about 10 breastfeeding women on treatment
Recruiting since March 2026; completion expected August 2027
Observational registryNCT07345494
Global pregnancy registry: outcomes for mothers and babies exposed during pregnancy or breastfeeding
Recruiting since February 2026; completion expected January 2036
Approval rests on one 26-week placebo-controlled trial of 82 adults, mostly women whose hypoparathyroidism followed neck surgery, plus open-label extensions now past 2 years. The kidney-function gains are post hoc and uncontrolled, and fractures weren’t studied. Few people over 65 took part, and higher adult doses, use in teens and use in pregnancy are still under study.
How it’s supplied
Ready-made pens in three strengths (300 mcg/mL), each with three dose settings from 6 to 30 mcg; one pen lasts 14 days. The pen measures each dose, so there’s nothing to mix or draw up.
Yorvipath comes as ready-made pens, not powder. Each pen color has three settings (blue 6, 9 or 12 mcg; orange 15, 18 or 21 mcg; burgundy 24, 27 or 30 mcg) and lasts 14 days. Delivered doses vary around the setting: the 6 mcg setting gives 4.5–7.5 mcg, which is why the US label allows only one injection a day.
Datasheet
Half-life
about 60 hoursLabelApparent half-life of the PTH released after subcutaneous injection; levels peak about 4 hours after a dose and reach steady state after about 7 days of daily dosing.
Type
Peptide, 34 amino acids
Molecular weight
about 47,400 g/mol (average, mostly the PEG carrier)
Formula
C209H340N60O59S3 plus 2 × (C2H4O)n, n about 450–500 (the label’s theoretical formula)
Sequence
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFTeriparatide), joined at its start through a self-cleaving linker to a branched 40 kDa methoxy-polyethylene glycol carrier
Storage before use
Not a powder: pens hold a ready-made solution. Until first use, refrigerate at 2–8 °C in the package to protect from light; don’t freeze or store near heat.
After mixing or opening
After first use, keep below 30 °C for 14 days, capped, with the needle removed; discard the pen 14 days after first use.
Half-life: Yorvipath prescribing information rev. 8/2026, section 12.3; same value in Karpf et al., J Bone Miner Res 2020, PMID 32212275
Molecule: Yorvipath label rev. 8/2026, section 11; FDA GSRS (UNII G2N64C3385). No PubChem compound record.
Storage:Label Yorvipath prescribing information rev. 8/2026, section 16.2
Doses are stated as PTH(1–34): each mL holds 3,456 mcg of the conjugate, equal to 300 mcg of PTH(1–34). Pens are dial-a-dose with three settings each, and the label gives a delivered range around each setting (4.5–7.5 mcg at 6 mcg).
Cautions
Blood calcium can go too high or too low, and serious cases have needed hospital care. Calcium is checked 7–10 days after every dose change and at least every 4–6 weeks.
Stopping suddenly or missing several days can cause low calcium; after 3 or more days without doses, the label says to check for it.
US label: never use two injections to make up one day’s dose, because the delivered amount becomes less predictable.
Related PTH drugs caused bone cancer (osteosarcoma) in rats; it isn’t recommended for people at higher risk, and long-term cancer studies of palopegteriparatide haven’t been done.
Dizziness and blood pressure drops on standing are common early on. Serious allergic reactions prompted a new US warning in August 2026, and digoxin needs close monitoring.
Questions
What is palopegteriparatide?
Teriparatide (PTH 1–34) attached to an inert polyethylene glycol carrier through a linker that slowly breaks apart, releasing PTH steadily around the clock. It replaces the missing hormone in hypoparathyroidism, keeping blood calcium normal.
How does palopegteriparatide work?
Palopegteriparatide is teriparatide, the active first 34 amino acids of parathyroid hormone (PTH), tied to an inert polyethylene glycol carrier by a linker that breaks apart on its own in the body, releasing PTH steadily over the day. Like natural PTH, it acts on the PTH1 receptor in bone and kidney: it frees calcium from bone, makes the kidneys keep calcium and shed phosphate, and boosts active vitamin D, which raises calcium absorption. Long-term effects on bone, kidney outcomes and fracture risk are still being studied; the kidney-function gains come from uncontrolled extension data. No long-term cancer studies in animals have been done.
Is palopegteriparatide FDA-approved?
Approved in the US on August 9, 2024 as Yorvipath for hypoparathyroidism in adults, after a 2023 rejection over variable pen doses. Not approved for children, and not studied for low calcium right after neck surgery.
What is the usual palopegteriparatide dose?
From the label (Yorvipath (US)): Starts at 18 mcg once a day, then moves up or down in 3 mcg steps by blood calcium (up no sooner than every 7 days, down no sooner than every 3). Usual range 6–30 mcg, always one injection; active vitamin D and calcium pills are cut back on day 1. Yorvipath (EU, UK, Australia): Same start and steps, but the range runs to 60 mcg a day; doses above 30 mcg are given as two injections from two pens at different sites. These are the amounts sources reference, not recommendations.
How is palopegteriparatide given?
Ready-made pens in three strengths (300 mcg/mL), each with three dose settings from 6 to 30 mcg; one pen lasts 14 days, injected under the skin. Once a day. If dizziness or a pounding heart follows injections, the label suggests dosing at bedtime while lying down. The pen measures each dose, so there’s nothing to mix.
Who should avoid palopegteriparatide?
Severe allergy to palopegteriparatide: Ruled out by the US label; anaphylaxis, angioedema (deep swelling of the face or throat) and hives have been reported, and a hypersensitivity warning was added in August 2026. Pseudohypoparathyroidism: Ruled out by the EU label. In this condition PTH levels are high, but the body resists their effects. Higher baseline risk of bone cancer: Not recommended (US) with open growth plates, Paget’s disease or other metabolic bone disease, unexplained high alkaline phosphatase, bone cancer or metastases, or past skeletal radiation. The “Who should avoid it” section lists 3 more groups and 2 interactions.
What is the half-life of palopegteriparatide?
About 60 hours, according to the prescribing information. Apparent half-life of the PTH released after subcutaneous injection; levels peak about 4 hours after a dose and reach steady state after about 7 days of daily dosing.
How should palopegteriparatide be stored?
Not a powder: pens hold a ready-made solution. Until first use, refrigerate at 2–8 °C in the package to protect from light; don’t freeze or store near heat. After first use, keep below 30 °C for 14 days, capped, with the needle removed; discard the pen 14 days after first use.
Is palopegteriparatide banned in sport?
No. Not named on the 2026 list, and S0 doesn’t apply to an approved drug. Parathyroid hormone and its analogs aren’t among the S2 peptide hormones or growth factors the list names.
Has palopegteriparatide been studied in people?
Yes. The human studies section lists 5 published studies. The largest, from 2023, included 82 people. 79% vs 5% on placebo had normal calcium without active vitamin D or therapeutic calcium (68.9% vs 4.8% by FDA’s stricter definition); 93% stopped conventional therapy.
How long has palopegteriparatide been studied in people?
Trial PaTH Forward: 57 adults on daily injections through week 162 (about 3 years). In PaTHway, 76 of 82 were still treated at 2 years.
Does palopegteriparatide come in other forms, like a pill or nasal spray?
Label Only daily injections under the skin from prefilled pens are approved; no other form has been tested in people.
Can you drink alcohol while taking palopegteriparatide?
Precaution The labels don’t address alcohol. Dizziness and blood pressure drops on standing are common early in treatment, and alcohol could add to them.
Can palopegteriparatide be taken with semaglutide or tirzepatide?
No study No study has combined them, and neither drug’s label lists an interaction between them.
What happens if you take too much palopegteriparatide?
Label Per the label, one trial patient who took about 3 times the prescribed dose for over a week reached calcium of 16.1 mg/dL and was hospitalized. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.